HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
TerminatedNCT00907218

Varenicline (Chantix) for ADHD

Medication studyAges 18–60
The study in practice

Understand this study

Who could participate?

Listed age limits: 18 years to 60 years.

Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateApril 2009
Recruitment status
Terminated
Enrollment listed in the registry
2
Sponsor
Massachusetts General Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
Not clearly listed
Age range
From 18 Years to 60 Years
Official registry ID
NCT00907218
Official title
Show the full official title

An Open Pilot Study of Varenicline (Chantix) in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD): Effects on ADHD and Cigarette Smoking

Recruitment & locations

Terminated

Locations not listed

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.

Does this study involve medication?

Yes. The study involves medication, including Varenicline (Chantix).

Who can participate?

Listed age limits: 18 years to 60 years.

Is this study still recruiting?

The registry lists this study as terminated.

Want to explore more studies?

Explore studies